JP Morgan analyst Paul Coster downgrades Plexus (NASDAQ:PLXS) from Neutral to Underweight.
After Positive Data In Ulcerative Colitis Study, Immunic Prioritizes Vidofludimus Calcium Program With One More Candidate
Immunic, Inc (NASDAQ:IMUX) reported data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset, vidofludimus calcium (IMU-838),…